Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Role of stereotactic radiosurgery for intracranial epidermoid tumors: a systematic review to assess its safety, efficacy, and complication profile.
J Neurooncol
January 2025
University of Virginia, Charlottesville, VA, USA.
Background: Even a gross total resection of a benign epidermoid tumor (ET) carries a high risk of recurrence. The management strategy mostly involves redo surgical excision but at a significant cost of morbidity and mortality. The role of adjuvant radiation therapies in this scenario is still undefined.
View Article and Find Full Text PDFAccelerated Low-Dose Total Skin Electron Beam Therapy Using the Modified Stanford Technique: An In Vivo Dosimetry Confirmation Study.
Cureus
December 2024
Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, USA.
Purpose Low-dose total skin electron beam therapy (LD-TSEBT) has recently gained popularity in treating mycosis fungoides (MF) due to its reduced toxicity and favorable response rates. Combining accelerated LD-TSEBT with the modified Stanford technique (mST), a condensed cycling approach, offers a promising and convenient option. However, in vivo dosimetry data confirming the effectiveness of this approach is limited.
View Article and Find Full Text PDFCharacterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort.
Radiat Oncol
January 2025
Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, P.R. China.
Aim: To characterize the differences of dynamic changes for absolute lymphocyte count (ALC) among esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant chemoradiotherapy (nCRT) with or without pembrolizumab, as well as to investigate the clinical and lymphocyte-related organs dosimetric parameters that would impact ALC nadir during nCRT.
Materials And Methods: A total of 216 ESCC patients who received nCRT (with pembrolizumab 144; without pembrolizumab: 72) were identified from a prospective cohort. Weekly and 1-month post-nCRT ALC were identified.
Gafchromic Films as a Complementary In-field Dosimetric Tool to Monitor Low Photon Radiation Doses (≤50 mSv).
Health Phys
January 2025
Department of Physics, Toronto Metropolitan University, 350 Victoria Street, Toronto, Ontario, M5B 2K3.
This study elucidated the radiation response characteristics of a Gafchromic radiochromic film subjected to low photon doses of ≤50 mSv, which corresponds to the annual whole body effective dose limit for radiation workers in Canada. Radiochromic films are investigated for possible use as a complementary tool for the Canadian Armed Forces that can be worn in addition to their existing personal dosimetry to quickly assess personal radiation dose received from radiological hazards without reliance on electronics. The films were exposed to varying photon energies emanating from x-ray generators and radioisotopes, specifically cesium-137, cobalt-60, and americium-241.
View Article and Find Full Text PDFMicrobeam Radiation Therapy Bio-Dosimetry Enhanced by Novel Radiosensitiser Combinations in the Treatment of Brain Cancer.
Cancers (Basel)
December 2024
Centre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW 2522, Australia.
: Brain cancer is notoriously resistant to traditional treatments, including radiotherapy. Microbeam radiation therapy (MRT), arrays of ultra-fast synchrotron X-ray beams tens of micrometres wide (called peaks) and spaced hundreds of micrometres apart (valleys), is an effective alternative to conventional treatments. MRT's advantage is that normal tissues can be spared from harm whilst maintaining tumour control.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!